TY  - GEN
AU  - Morschhauser,F
AU  - Recher,C
AU  - Milpied,N
AU  - Gressin,R
AU  - Salles,G
AU  - Brice,P
AU  - Vey,N
AU  - Haioun,C
AU  - Colombat,P
AU  - Rossi,J F
AU  - Deconinck,E
AU  - Lazreg,F
AU  - Bergougnoux,L
AU  - Delsol,G
AU  - Attal,M
TI  - A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients with follicular lymphoma
SN  - 1569-8041
PY  - 2013///0329
KW  - Adolescent
KW  - Adult
KW  - Aged
KW  - Antibodies, Monoclonal, Murine-Derived
KW  - therapeutic use
KW  - Antineoplastic Agents
KW  - Hematopoietic Stem Cell Transplantation
KW  - Humans
KW  - Lymphoma, Follicular
KW  - drug therapy
KW  - Middle Aged
KW  - Neoplasm, Residual
KW  - Polymerase Chain Reaction
KW  - Prospective Studies
KW  - Rituximab
KW  - Young Adult
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1093/annonc/mds202
ER  -